Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy

Laura N. Eadie; Elias Lagonik; Elyse C. Page; Caitlin E. Schutz; Susan L. Heatley; Barbara J. McClure; Michelle O. Forgione; David T. Yeung; Timothy P. Hughes; Deborah L. White

doi:10.1182/blood.2024024776

Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy

Laura N. Eadie, Elias Lagonik, Elyse C. Page, Caitlin E. Schutz, Susan L. Heatley, Barbara J. McClure, Michelle O. Forgione, David T. Yeung, Timothy P. Hughes, Deborah L. White

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Blood
DOIs	https://doi.org/10.1182/blood.2024024776
Publication status	Accepted/In press - 2024

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood.2024024776

Cite this

@article{4faf9b063ba2485cae825d943863079e,

title = "Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy",

author = "Eadie, {Laura N.} and Elias Lagonik and Page, {Elyse C.} and Schutz, {Caitlin E.} and Heatley, {Susan L.} and McClure, {Barbara J.} and Forgione, {Michelle O.} and Yeung, {David T.} and Hughes, {Timothy P.} and White, {Deborah L.}",

year = "2024",

doi = "10.1182/blood.2024024776",

language = "English",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

}

TY - JOUR

T1 - Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy

AU - Eadie, Laura N.

AU - Lagonik, Elias

AU - Page, Elyse C.

AU - Schutz, Caitlin E.

AU - Heatley, Susan L.

AU - McClure, Barbara J.

AU - Forgione, Michelle O.

AU - Yeung, David T.

AU - Hughes, Timothy P.

AU - White, Deborah L.

PY - 2024

Y1 - 2024

UR - http://www.scopus.com/inward/record.url?scp=85198326470&partnerID=8YFLogxK

U2 - 10.1182/blood.2024024776

DO - 10.1182/blood.2024024776

M3 - Article

C2 - 38848536

AN - SCOPUS:85198326470

SN - 0006-4971

JO - Blood

JF - Blood

ER -

Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this